Test ID: LMPP
Lipoprotein Metabolism Profile
NY State Approved
Indicates the status of NY State approval and if the test is orderable for NY State clients.
Useful For
Suggests clinical disorders or settings where the test may be helpful
Determining the existence and type of dyslipoproteinemia
Quantitation of cholesterol and triglycerides in VLDL, LDL, HDL, Lp(a), and any other significant lipoprotein fractions.
Classifying hyperlipoproteinemias (lipoprotein phenotyping)
Evaluating patients with abnormal lipid values (cholesterol, triglyceride, HDL, LDL)
Quantifying Lp(a) cholesterol
Profile Information
A profile is a group of laboratory tests that are ordered and performed together under a single Mayo Test ID. Profile information lists the test performed, inclusive of the test fee, when a profile is ordered and includes reporting names and individual availability.
| Test ID | Reporting Name | Available Separately | Always Performed |
|---|---|---|---|
| TCS | Cholesterol, Total, CDC, S | No | Yes |
| TRIGC | Triglycerides, CDC, S | No | Yes |
| APLBS | Apolipoprotein B, S | No | Yes |
| HDLS | HDL Cholesterol, CDC, S | No | Yes |
| LMPP1 | Lipoprotein Metabolism Profile 1 | No | Yes |
Special Instructions and Forms
Describes specimen collection and preparation information, test algorithms, and other information pertinent to test. Also includes pertinent information and consent forms to be used when requesting a particular test
Method Name
A short description of the method used to perform the test
Ultracentrifugation/Electrophoresis/Automated Enzymatic/Colorimetric Analysis
Reporting Name
A shorter/abbreviated version of the Published Name for a test; an abbreviated test name
Aliases
Lists additional common names for a test, as an aid in searching
Cardiac Lipoprotein Phenotyping
Cholesterol, LDL (Low Density Lipoprotein)
Chlyomicron
Fredrickson Phenotyping
HDC (High-Density Cholesterol)
HDL (High-Density Lipoprotein) Cholesterol
HDT (High-Density Triglyceride)
High-Density Cholesterol (HDC)
High-Density Lipoprotein (HDL) Cholesterol
High-Density Triglyceride (HDT)
Intermediate Density Lipoprotein
LDL (Low-Density Lipoprotein)
LDL (Low-Density Lipoprotein) Cholesterol
Lipid Phenotyping
Lipid Profile
Lipoprotein Electrophoresis
Lipoprotein Frationation
Lipoprotein Phenotyping
Low-Density Lipoprotein (LDL)
Low-Density Lipoprotein (LDL) Cholesterol
Lp(a) Cholesterol
LPX
VLDL (Very Low Density Lipoprotein)
Specimen Type
Describes the specimen type needed for testing
Specimen Required
Defines the optimal specimen. This field describes the type of specimen required to perform the test and the preferred volume to complete testing. The volume allows automated processing, fastest throughput and, when indicated, repeat or reflex testing.
Collection Container/Tube:
Preferred: Red top
Acceptable: Serum gel
Submission Container/Tube: Plastic vial
Specimen Volume: 5 mL
Collection Instructions:
1. Fasting-overnight (12-14 hours)
2. Patient must not consume any alcohol for 24 hours before the specimen is drawn.
Additional Information: Patient's age and sex are required.
Forms: If not ordering electronically, submit a General Request Form (Supply T239) with the specimen.
Specimen Minimum Volume
Defines the amount of specimen required to perform an assay once, including instrument and container dead space. Submitting the minimum specimen volume makes it impossible to repeat the test or perform confirmatory or perform reflex testing. In some situations, a minimum specimen volume may result in a QNS (quantity not sufficient) result, requiring a second specimen to be collected.
Reject Due To
Identifies specimen types and conditions that may cause the specimen to be rejected
| Hemolysis | Mild OK; Gross reject |
| Lipemia | Mild OK; Gross OK |
| Icterus | Mild OK; Gross reject |
| Other | NA |
Specimen Stability Information
Provides a description of the temperatures required to transport a specimen to the laboratory. Alternate acceptable temperature(s) are also included.
| Specimen Type | Temperature | Time |
|---|---|---|
| Serum | Refrigerated (preferred) | 7 days |
| Frozen | 60 days |
Clinical Information
Discusses physiology, pathophysiology, and general clinical aspects, as they relate to a laboratory test
Levels of total cholesterol and triglycerides are dependent on age, sex, diet, physical activity profile, and the presence or absence of inheritable and nonheritable metabolic problems. Abnormalities in the serum lipoprotein profile can suggest various problems in metabolism, liver function, and renal function, in addition to being reflections of problems in lipid transport.
Increased levels of low-density lipoprotein (LDL) and cholesterol-rich, small-particle, very low-density lipoprotein (VLDL), which are seen in type III hyperlipoproteinemia, are risk factors for atherosclerotic disease. Increased high-density lipoprotein (HDL) levels are considered favorable in relation to atherosclerotic disease.
While serum total cholesterol and HDL cholesterol values may be adequate for evaluation of some patients, for many patients an adequate evaluation can be accomplished only with examination of the entire lipoprotein profile. Analysis of serum lipoproteins may be of use if the patient's cholesterol, triglycerides, HDL, or LDL are abnormal (ie, outside the guidelines established by the National Cholesterol Education Program). In these patients, measurement of only total cholesterol or triglycerides does not provide sufficient information and may be misleading.
Care must be taken in the interpretation of apparent hypercholesterolemia (increased total cholesterol), since it can reflect an increased LDL with an increased risk for atherosclerotic disease, or a high level of HDL with a reduced risk. While hypercholesterolemia is often considered to be an expression of an increased concentration of LDL (type IIa hyperlipoproteinemia), in some patients increased total cholesterol levels reflect increased levels of other lipoproteins (eg, HDL, VLDL, or chylomicrons). In addition, hypercholesterolemia can reflect the presence of "LP-X," the abnormal lipoprotein complex associated with cholestasis or anomalous conditions. Hypercholesterolemia can best be identified through the combination of electrophoretic screening and quantitative testing, with the quantitative method determined by the forms of lipoproteins that are prominent in the electrophoretogram.
Identification of patients with type III hyperlipoproteinemia may be helpful for optimal patient management; analysis of VLDL particles is necessary to identify these patients. VLDL and HDL contain varying amounts of cholesterol, triglycerides, and phospholipids; the cholesterol and triglyceride content in these fractions has clinical significance. A definitive analysis must include establishing the presence of an increased population of cholesterol-rich VLDL particles of sizes that are much smaller than the primary VLDL particles; evaluation of the cholesterol:triglyceride ratio in the isolated total VLDL fraction is a necessary step in diagnosis.
A high level of HDL may or may not reflect a healthy status. In a person free of liver disease or intoxication of any form, a high level of HDL is an indication of a healthy metabolic system and probably indicates a relatively low risk for atherosclerotic disease. Otherwise, a high level of HDL may reflect the existence of an early stage of primary biliary cirrhosis, chronic hepatitis, alcoholism, or some other form of chronic intoxication. This interpretational problem is readily resolvable through simple quantitative testing involving ultracentrifugation, selective precipitation, or a combination of these methods.
Classifying the hyperlipoproteinemias into phenotypes has limited value for the evaluation of genetic traits, but does place disorders that affect plasma lipid and lipoprotein concentrations into convenient groups for evaluation and treatment. A clear distinction must be made between primary (inherited) and secondary (liver disease, alcoholism, metabolic diseases) causes of dyslipoproteinemia.
Reference Values
Describes reference intervals and additional information for interpretation of test results. May include intervals based on age and sex when appropriate. Intervals are Mayo-derived, unless otherwise designated. If an interpretive report is provided, the reference value field will state this.
The National Cholesterol Education Program (NCEP) has set the following guidelines for lipids (total cholesterol, triglycerides, HDL, and LDL cholesterol) in adults ages 18 and up:
TOTAL CHOLESTEROL
Optimal: <200 mg/dL
Borderline high: 200-239 mg/dL
High: > or =240 mg/dL
TRIGLYCERIDES
Normal: <150 mg/dL
Borderline: 150-199 mg/dL
High: 200-499 mg/dL
Very high: > or =500 mg/dL
HDL CHOLESTEROL
Low: <40 mg/dL
Normal: 40-59 mg/dL
Desirable: > or =60 mg/dL
LDL CHOLESTEROL
Optimal: <100 mg/dL
Near Optimal: 100-129 mg/dL
Borderline: 130-159 mg/dL
High: 160-189 mg/dL
Very high: > or =190 mg/dL
The National Cholesterol Education Program (NCEP) and National Health and Nutrition Examination Survey (NHANES) have set the following guidelines for lipids (total cholesterol, triglycerides, HDL, and LDL cholesterol) in children ages 2-17:
TOTAL CHOLESTEROL
Desirable: <170 mg/dL
Borderline high: 170-199 mg/dL
High: > or =200 mg/dL
TRIGLYCERIDES
Normal: <90 mg/dL
Borderline high: 90-129 mg/dL
High: > or =130 mg/dL
HDL CHOLESTEROL
Low: <40 mg/dL
Normal: 40-59 mg/dL
Desirable: > or =60 mg/dL
LDL CHOLESTEROL
Desirable: <110 mg/dL
Borderline high: 110-129 mg/dL
High: > or =130 mg/dL
APOLIPOPROTEIN B
Males and females > or =18 years: 48-124 mg/dL
VLDL CHOLESTEROL
<30 mg/dL
VLDL TRIGLYCERIDES
<120 mg/dL
BETA-VLDL CHOLESTEROL
<15 mg/dL
BETA-VLDL TRIGLYCERIDES
<15 mg/dL
CHYLOMICRON CHOLESTEROL
Undetectable
CHYLOMICRON TRIGLYCERIDES
Undetectable
Lp(a) CHOLESTEROL
Desirable: <3 mg/dL
Values > or =3 mg/dL may suggest increased risk of coronary artery disease.
LpX
Undetectable
Also see age- and sex-adjusted reference values in Lipid Reference Values for Lipoprotein Profile in Lipids and Lipoproteins in Blood Plasma (Serum) in Special Instructions.
Interpretation
Provides information to assist in interpretation of the test results
For discussion of various lipoprotein fractions, see Clinical Information.
For a discussion of Lp(a), see LPAWS/89005 Lipoprotein (a) Cholesterol, Serum
For treatment recommendations, see Lipids and Lipoproteins in Blood Plasma (Serum), National Cholesterol Education Program Guidelines, in Special Instructions.
Cautions
Discusses conditions that may cause diagnostic confusion, including improper specimen collection and handling, inappropriate test selection, and interfering substances
Reference values are based on fasting collections; it is essential that the patient fasts 12 to 14 hours before the test.
Clinical Reference
Provides recommendations for further in-depth reading of a clinical nature
1. Schriver CR, Beaudet AL, Sly WS, Valle D: Lipoprotein and lipid disorders. In The Metabolic Basis of Inherited Disease. Sixth edition. Edited by JB Stanbury, JB Wyngaarden, DS Frederickson. New York, McGraw-Hill Book Company, 1989, pp 1129-1302
2. Grinstead GF, Ellefson RD: Heterogeneity of lipoprotein Lp(a) and apolipoprotein(a). Clin Chem 1988;34:1036-1040
Method Description
Describes how the test is performed and provides a method-specific reference
Serum lipoproteins are surveyed by a combination of electrophoresis, ultracentrifugation, and automated enzymatic quantitation of cholesterol and triglycerides in the quantitatively significant fractions (HDL, LDL, VLDL, and Lp[a]) to evaluate the lipoproteinemias accurately.(Ellefson RD, Jiminez BJ, Smith RC: Pre-beta [or alpha-2] lipoprotein of high density in human blood. Mayo Clin Proc 1971;46:328-332; Ellefson RD, Caraway RT: Lipids and lipoproteins. In Fundamentals of Clinical Chemistry. Edited by NW Tietz, Philadelphia, WB Saunders Company, 1976, pp 474-541; Baudhuin LM, Hartman SJ, O'Brien JF, et al: Electrophoretic measurement of lipoprotein[a] cholesterol in plasma with and without ultracentrifugation: comparison with an immunoturbidimetric lipoprotein[a] method. Clin Biochem 2004;37[6]:481-488)
Day(s) and Time(s) Test Performed
Outlines the days and times the test is performed. This field reflects the day and time the sample must be in the testing laboratory to begin the testing process and includes any specimen preparation and processing time required before the test is performed. Some tests are listed as continuously performed, which means assays are performed several times during the day.
Monday through Thursday, Sunday; 3 p.m.
Analytic Time
Defines the amount of time it takes the laboratory to setup and perform the test. This is defined in number of days. The shortest interval of time expressed is "same day/1 day," which means the results may be available the same day that the sample is received in the testing laboratory. One day means results are available 1 day after the sample is received in the laboratory.
Maximum Laboratory Time
Defines the maximum time from specimen receipt at Mayo Medical Laboratories until the release of the test result
Performing Laboratory Location
The location of the laboratory that performs the test
CPT Code Information
Provides guidance in determining the appropriate Current Procedural Terminology (CPT) code(s) information for each test or profile. The listed CPT codes reflect Mayo Medical Laboratories interpretation of CPT coding requirements. It is the responsibility of each laboratory to determine correct CPT codes to use for billing.
80061-Lipid panel (includes: HDL [CPT Code 83718], total cholesterol [CPT Code 82465], and triglycerides [CPT Code 84478])
82172-Apolipoprotein B
82664-Lp(a) cholesterol electrophoresis
LOINC® Code Information
Provides guidance in determining the Logical Observation Identifiers Names and Codes (LOINC) values for the result codes returned for this test or profile.
| Result ID | Reporting Name | LOINC Code |
|---|---|---|
| TCS | Cholesterol, Total, CDC, S | 2093-3 |
| HDLS | HDL Cholesterol, CDC, S | 2085-9 |
| TRIGC | Triglycerides, CDC, S | 2571-8 |
| APLBS | Apolipoprotein B, S | 1884-6 |
| 2839 | LDL Cholesterol | 2089-1 |
| 2840 | LDL Triglycerides | 3046-0 |
| 2844 | VLDL cholesterol | 2091-7 |
| 2847 | VLDL triglycerides | 3047-8 |
| 2842 | Beta VLD Cholesterol | 2091-7 |
| 2843 | Beta VLDL triglycerides | 3045-2 |
| 2855 | Chylomicron cholesterol | 34467-1 |
| 2856 | Chylomicron triglycerides | 35363-1 |
| 2849 | Lp(a) Cholesterol | 10835-7 |
| 23924 | LpX | 42178-4 |
| 23937 | Interpretation | 59462-2 |


